Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)
Key Points
Key points are not available for this paper at this time.
Abstract
3517
KI fragen
Like
Bookmark
Share
KI fragen
Like
Bookmark
Share
Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC) | Synapse